Kodiak Sciences (KOD) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Twist Bioscience (TWST) over the past year, gaining 367.8% versus a gain of 261.8%. Over five years, TWST leads with a +8.8% price change compared with +3.0% for KOD. Twist Bioscience is the larger company by market cap ($7.04 billion vs $6.35 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | TWST |
|---|---|---|
| Share price | $97.17 | $103.32 |
| Market cap | $6.35B | $7.04B |
| 1-day change | -0.75% | -7.44% |
| YTD return | +247.53% | +225.73% |
| 1-year return | +367.84% | +261.76% |
| 5-year return | +3.04% | +8.77% |
| EPS (TTM) | $-4.08 | $-2.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $459.43M |
| Revenue growth (YoY) | — | +22.00% |
| Net income (latest FY) | $-229.97M | $-130.20M |
| Gross margin | — | 52.41% |
| Operating margin | — | -30.35% |
| Net margin | — | -28.34% |
| 52-week high | $112.79 | $219.71 |
| 52-week low | $20.38 | $28.27 |
| Distance from 52-week high | -13.85% | -52.97% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +33.27% | +24.68% |
| Average volume | 1.77M | 2.49M |
| Shares outstanding | 65.40M | 68.18M |
| Employees | 144 | 1,080 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed TWST by 106.1 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees
KOD vs TWST FAQ
Which is bigger, Kodiak Sciences or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $6.35B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, KOD or TWST?
KOD returned +367.84% over the past 12 months, compared with +261.76% for TWST (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.